Key Laboratory for Advanced Materials & Institute of Fine Chemicals and School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, People's Republic of China.
Glycoconj J. 2011 Oct;28(7):493-7. doi: 10.1007/s10719-011-9347-0. Epub 2011 Sep 6.
There has been increasing interest in the development of drug candidates based on sugar templates that possess rich structural and, especially, configurational diversities. We disclose herein that the epimeric identity between methyl 3,4-bis-phenylalanyl/tyrosinyl triazolyl-alpha-D-galactopyranoside and glucopyranoside may lead to their distinct inhibitory effects on specific protein tyrosine phosphatases (PTPs). Subsequently performed molecular docking study elucidated the plausible binding behaviors of the more potent galactosyl inhibitors with their primary PTP target, i.e. Cell Division Cycle 25B (CDC25B) phosphatase.
人们对基于糖模板的候选药物的开发越来越感兴趣，这些药物具有丰富的结构和构象多样性。我们在此披露，甲基 3,4-双苯丙氨酰/酪氨酸三唑基-α-D-半乳糖吡喃糖苷和吡喃葡萄糖苷之间的差向异构体身份可能导致它们对特定蛋白酪氨酸磷酸酶（PTP）具有不同的抑制作用。随后进行的分子对接研究阐明了更有效的半乳糖基抑制剂与它们的主要 PTP 靶标，即细胞分裂周期 25B（CDC25B）磷酸酶的可能结合行为。
